NasdaqGM:APGEBiotechs
Apogee Therapeutics (APGE) To Showcase APG777 At EADV Congress 2025
Apogee Therapeutics (APGE) made headlines with the acceptance of data from its Phase 2 APEX trial for APG777 at the EADV Congress, signaling its efforts in tackling atopic dermatitis. Over the last month, Apogee’s share price rose 1.55%, reflecting a performance consistent with the broader market's 1.8% increase. While its clinical developments added momentum, other market trends such as the Nasdaq’s record highs and tech sector rallies also buoyed investor confidence. These factors...